共 50 条
- [31] Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trialBREAST, 2021, 56 : S19 - S19Martin, M.Holmes, F. A.Moy, B.Mansi, J.Gnant, M.Buyse, M.Barrios, C.Bryce, R.Wong, A.Chan, A.
- [32] HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation TrialJAMA ONCOLOGY, 2017, 3 (08) : 1094 - 1101Ahmed, NabilBrawley, VitaHegde, MeenakshiBielamowicz, KevinKalra, MamtaLandi, DanielRobertson, CatherineGray, Tara L.Diouf, OumarWakefield, AmandaGhazi, AlexiaGerken, ClaudiaYi, ZhongzhenAshoori, AidinWu, Meng-FenLiu, HaoRooney, ClionaDotti, GianpietroGee, AdrianSu, JackKew, YvonneBaskin, DavidZhang, Yi JonathanNew, PamelaGrilley, BambiStojakovic, MilicaHicks, JohnPowell, Suzanne Z.Brenner, Malcolm K.Heslop, Helen E.Grossman, RobertWels, Winfried S.Gottschalk, Stephen
- [33] Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial (vol 14, pg 88, 2013)LANCET ONCOLOGY, 2013, 14 (02): : E47 - E47Goss, P. E.Smith, I. E.O'Shaughnessy, J.
- [34] Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trialNATURE MEDICINE, 2025, 31 (02) : 442 - 448Cardoso, FatimaO'Shaughnessy, JoyceLiu, ZhenzhenMcarthur, HeatherSchmid, PeterCortes, JavierHarbeck, NadiaTelli, Melinda L.Cescon, David W.Fasching, Peter A.Shao, ZhiminLoirat, DelphinePark, Yeon HeeFernandez, Manuel GonzalezRubovszky, GaborSpring, LauraIm, Seock-AhHui, RinaTakano, ToshimiAndre, FabriceYasojima, HiroyukiDing, YuJia, LiyiKarantza, VassilikiTryfonidis, KonstantinosBardia, Aditya
- [35] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialCLINICAL BREAST CANCER, 2021, 21 (01) : 80 - +Chan, ArleneMoy, BeverlyMansi, JanineEjlertsen, BentHolmes, Frankie AnnChia, StephenIwata, HirojiGnant, MichaelLoibl, SibylleBarrios, Carlos H.Somali, IsilSmichkoska, SnezhanaMartinez, NoeliaAlonso, Mirta GarciaLink, John S.Mayer, Ingrid A.Cold, SorenMurillo, Serafin MoralesSenecal, FrancisInoue, KenichiRuiz-Borrego, ManuelHui, RinaDenduluri, NeelimaPatt, DebraRugo, Hope S.Johnston, Stephen R. D.Bryce, RichardZhang, BoXu, FengWong, AlvinMartin, Miguel
- [36] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyBRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1086 - 1093Munster, PamelaKrop, Ian E.LoRusso, PatriciaMa, CynthiaSiegel, Barry A.Shields, Anthony F.Molnar, IstvanWickham, Thomas J.Reynolds, JosephCampbell, KarenHendriks, Bart S.Adiwijaya, Bambang S.Geretti, ElenaMoyo, VictorMiller, Kathy D.
- [37] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studyLANCET ONCOLOGY, 2019, 20 (06): : 816 - 826Tamura, KenjiTsurutani, JunjiTakahashi, ShunjiIwata, HirojiKrop, Ian E.Redfern, CharlesSagara, YasuakiDoi, ToshihikoPark, HaeseongMurthy, Rashmi K.Redman, Rebecca A.Jikoh, TakahiroLee, CalebSugihara, MasahiroShahidi, JavadYver, AntoineModi, Shanu
- [38] A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Im, Seock-AhJuric, DejanBaselga, JoseKong, AnthonyMartin, PalomaLin, Chia-ChiDees, Elizabeth ClaireSchellens, Jan H. M.De Braud, Filippo G.Delgado, LilyZucchetto, MauroTian, XianbinFernandez, RoseMorozov, AlexDirix, Luc Yves
- [40] PHASE II TRIAL OF RIFAXIMIN IN PATIENTS WITH EARLY-STAGE HER2 POSITIVE BREAST CANCER WITH GASTROINTESTINAL TOXICITIES RELATED TO PERTUZUMAB-BASED THERAPYGASTROENTEROLOGY, 2024, 166 (05) : S1034 - S1034Roque, Maria VazquezJohnson, StephenLiu, HeshanWeidner, MorganCornell, LaurenRoseberry, BeverlySahni, SabrinaAdvani, PoojaErnst, BrendaRao, RohitSideras, KostandinosMoreno-Aspitia, Alvaro